P2Y12 receptor antagonists: A rapidly expanding group of antiplatelet agents

European Heart Journal

Volumn 27, Issue 9, 2006, Pages 1010-1012

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARC 109318XX; CANGRELOR; CLOPIDOGREL; PRASUGREL; PURINE P2Y12 RECEPTOR; PURINE P2Y12 RECEPTOR ANTAGONIST; PURINERGIC RECEPTOR BLOCKING AGENT; TICLOPIDINE; UNCLASSIFIED DRUG; ADENOSINE; DRUG DERIVATIVE; PURINE P2 RECEPTOR;

BLEEDING; CLINICAL TRIAL; DRUG SAFETY; DYSPNEA; EDITORIAL; HUMAN; ISCHEMIC HEART DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; ATHEROSCLEROSIS; DRUG ANTAGONISM; NOTE;

ADENOSINE; ATHEROSCLEROSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2;

EID: 33646253693     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi851     Document Type: Editorial

References (10)

1. Cattaneo M. The platelet P2 receptors. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2006, in press.
2. Cattaneo M. ADP receptors antagonists. In: Michelson AD, ed. Platelets. San Diego, CA: Academic Press; 2006, in press.
3. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D, Hirsh J, Husted S, Kvasnicka J, Montalescot G, Garcia Rodriguez LA, Verheugt F, Vermylen J, Wallentin L, Priori SG, Alonso Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Morais J, Deckers J, Ferreira R, Mazzotta G, Steg PG, Teixeira F, Wilcox R. European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166-181.
4. Cattaneo M. Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004;24:1980-1987.
5. 12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-194.
6. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
7. Nurden AT, Nurden P. Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003;23:158-159.
8. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047. First published on February 13, 2006, doi:10.1093/eurheartj/ehi754.
9. van Giezen JJJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005;31:195-204.
10. Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140, an oral reversible ADP receptor antagonist. Haematologica 2004;89(Suppl. 7):14.